## metadata
source file: data/floodlamp/reg/fda-townhalls/f5_fixnames/run_auto/2021-09-08_Virtual Town Hall 69_fixnames.md
last updated: 2025-01-04 Created QA Sections
link pdf: https://www.fda.gov/media/152755/download?attachment
link youtube: https://youtu.be/XwF2qXapzBc
link slides: 
topic: COVID-19


## content

### qa


#### 1. COVID-19 Test Development and Authorization Guidelines Presentation

QA Block 1-1
CLARIFIED QUESTION: What are the considerations for starting validation studies within the US versus outside the US for SARS-CoV-2 tests?
CLARIFIED ANSWER: FDA recommends starting SARS-CoV-2 test validation studies in the US, especially for point-of-care or home tests, due to the availability of positive patient samples. If there are obstacles in obtaining enough positive samples, developers can consult FDA about conducting studies outside the US. For panel tests, testing outside the US may be an option where flu is more prevalent.
VERBATIM QUESTION: What are the considerations for starting validation studies within the US versus outside the US for SARS-CoV-2 tests?
VERBATIM ANSWER: I do want to remind those that have been inquiring through perhaps the pre-EUA process about OUS, or outside the US, studies for SARS, since there are plenty of patients, positive patients in the US, and as I've said before-- we said before that we really want you to start your studies in the US where possible and especially for point of care and home diagnostic tests. And that only if you run into hurdles about getting enough positive patients you reach out to us and find ways that you can perhaps go outside the US. Regarding panel tests which we'll talk about a little bit more later, in the US right now there's hardly any flu circulating. And there may be parts of the world where there's more flu and obviously for panel tests, it may be easier in some cases to get positives outside the US, so that's still one caveat.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation study location, Point-of-care/home diagnostics, Panel tests
REVIEW FLAG: False

QA Block 1-2
CLARIFIED QUESTION: What should developers do if they face challenges in obtaining sufficient positive patient samples in the US for SARS-CoV-2 test validation studies?
CLARIFIED ANSWER: Developers should start validation studies for SARS-CoV-2 tests in the US, especially for point-of-care and home tests. If challenges arise in obtaining enough positive samples, they should contact the FDA to explore options, including conducting studies outside the US.
VERBATIM QUESTION: What should developers do if they face challenges in obtaining sufficient positive patient samples in the US for SARS-CoV-2 test validation studies?
VERBATIM ANSWER: We note, unfortunately, that COVID infections are very prevalent in the US today as they are in many parts of the world. I do want to remind those that have been inquiring through perhaps the pre-EUA process about OUS, or outside the US, studies for SARS, since there are plenty of patients, positive patients in the US, and as I've said before-- we said before that we really want you to start your studies in the US where possible and especially for point of care and home diagnostic tests. And that only if you run into hurdles about getting enough positive patients you reach out to us and find ways that you can perhaps go outside the US.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: SARS-CoV-2 test validation, Positive patient sample availability, FDA contact for assistance
REVIEW FLAG: False

QA Block 1-3
CLARIFIED QUESTION: How should panel tests be validated when certain analytes, such as flu A/B, are not circulating widely in the US?
CLARIFIED ANSWER: FDA recommends using fresh samples for validation of panel tests, specifically for non-SARS viruses like flu A/B. Banked or contrived samples are not recommended. Developers can either use fully authorized existing assays to assess these analytes or consider blocking or not identifying signals for analytes lacking fresh samples.
VERBATIM QUESTION: How should panel tests be validated when certain analytes, such as flu A/B, are not circulating widely in the US?
VERBATIM ANSWER: We recommend fresh samples. Banked or even contrived samples for non-SARS viruses are going to be-- are not something that we recommend. There are, at least in the point of care in central lab, there are a number of flu AB or RSV assays that are fully authorized that can be used to assess patients for them. So if you are developing a panel assay where it's challenging because, especially for antigen, we're going to recommend that you have fresh samples. We recommend that you consider a ways of getting your SARS analytes authorized and somehow blocking the signal or not identifying the signal for any other analytes you might have on that panel for which you don't have available fresh samples to validate the assay.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Panel test validation, Flu A/B testing, Fresh sample requirement
REVIEW FLAG: False

QA Block 1-4
CLARIFIED QUESTION: Why are fresh samples recommended for validating home diagnostic assays, particularly for non-SARS viruses?
CLARIFIED ANSWER: The FDA recommends fresh samples for validating home diagnostic assays, particularly for non-SARS viruses, because banked or contrived samples are not reliable for this purpose. Fully authorized flu AB or RSV assays are available to assess patients in point of care or central labs.
VERBATIM QUESTION: Why are fresh samples recommended for validating home diagnostic assays, particularly for non-SARS viruses?
VERBATIM ANSWER: For antigen tests in particular and for all home diagnostic assays, we do recommend fresh samples. Banked or even contrived samples for non-SARS viruses are going to be-- are not something that we recommend. There are, at least in the point of care in central lab, there are a number of flu AB or RSV assays that are fully authorized that can be used to assess patients for them. So if you are developing a panel assay where it's challenging because, especially for antigen, we're going to recommend that you have fresh samples.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation of home diagnostic assays, Use of fresh samples, Non-SARS viruses
REVIEW FLAG: False

QA Block 1-5
CLARIFIED QUESTION: In cases where fresh samples are unavailable for panel tests, what is the FDA's specific recommendation for handling the non-SARS analytes?
CLARIFIED ANSWER: FDA recommends using fresh samples for panel tests and does not endorse banked or contrived samples for non-SARS analytes. Developers should find ways to block or not identify non-SARS analytes lacking fresh sample validation.
VERBATIM QUESTION: In cases where fresh samples are unavailable for panel tests, what is the FDA's specific recommendation for handling the non-SARS analytes?
VERBATIM ANSWER: For antigen tests in particular and for all home diagnostic assays, we do recommend fresh samples. Banked or even contrived samples for non-SARS viruses are going to be-- are not something that we recommend. There are, at least in the point of care in central lab, there are a number of flu AB or RSV assays that are fully authorized that can be used to assess patients for them. So if you are developing a panel assay where it's challenging because, especially for antigen, we're going to recommend that you have fresh samples. We recommend that you consider a ways of getting your SARS analytes authorized and somehow blocking the signal or not identifying the signal for any other analytes you might have on that panel for which you don't have available fresh samples to validate the assay.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Panel tests, Fresh samples, Non-SARS analytes
REVIEW FLAG: False

QA Block 1-6
CLARIFIED QUESTION: How is the FDA currently prioritizing antigen test submissions for review and authorization?
CLARIFIED ANSWER: The FDA is currently prioritizing antigen submissions by reviewing tests on a first-come, first-served basis when they are of relatively equivalent priority.
VERBATIM QUESTION: How is the FDA currently prioritizing antigen test submissions for review and authorization?
VERBATIM ANSWER: As we move forward, particularly for the antigen submissions, we are moving towards-- we've noted that in many cases, the relative priorities of antigen submissions, at this time at least, is relatively equivalent. So we are moving, and I've directed the team to move, to making sure that first in for these tests that are in this category of being roughly equivalent, that generally we will review them on a first come, first serve basis, a first in, would likely get-- we endeavor to get comments back or other feedback back or potentially authorizations first.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA antigen test prioritization, Review process, Diagnostic submissions
REVIEW FLAG: False

QA Block 1-7
CLARIFIED QUESTION: What are the current high-priority areas for serology tests from the FDA's perspective?
CLARIFIED ANSWER: The FDA's high-priority areas for serology tests are quantitative tests traceable to the international WHO standard and neutralizing antibody serology tests.
VERBATIM QUESTION: What are the current high-priority areas for serology tests from the FDA's perspective?
VERBATIM ANSWER: For serology, the highest priority tests are quantitative tests that are traceable to the international WHO standard as well as neutralizing antibody serology tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: High-priority serology tests, FDA priorities, Serology test criteria
REVIEW FLAG: False

QA Block 1-8
CLARIFIED QUESTION: What guidelines exist for implementing changes to EUA-authorized devices before authorization of the modification, especially concerning different testing environments (e.g., high complexity labs versus home use)?
CLARIFIED ANSWER: Modifications to EUA-authorized devices can only be implemented prior to authorization in high complexity labs. Moderately complex, point-of-care, or home environments must wait for EUA authorization. The policy guidance specifies that tests are limited to labs certified for high complexity under CLIA unless expanded by an EUA.
VERBATIM QUESTION: What guidelines exist for implementing changes to EUA-authorized devices before authorization of the modification, especially concerning different testing environments (e.g., high complexity labs versus home use)?
VERBATIM ANSWER: One other item we wish to note is that for kit developers that are implementing changes to their EUA authorized devices, when you implement a change prior to EUA authorization of that change, that's only going to be relevant to high complexity labs. So other labs or home situations, whether that be moderately complex or point of care or home, are not going to be able to be implemented prior to authorization. So reading from the COVID test policy guidance as well as FAQs, "Unless and until an EUA is issued that authorizes additional testing environments for a specific test under CLIA, use of that test is limited to laboratories certified to perform high complexity testing and including testing at the point of care when the site is covered by the laboratory's CLIA certificate for high complexity testing." End quote. So again, for implementation of modifications, those can be implemented prior to EUA authorization in a high complexity environment.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA changes, CLIA certifications, Testing environment limitations
REVIEW FLAG: False


#### 2. FDA Process for COVID Test Authorizations and Prioritizations

QA Block 2-1
CLARIFIED QUESTION: When will COVID-19 tests begin receiving full clearance?
CLARIFIED ANSWER: The FDA granted full authorization for the first COVID-19 molecular test in March (BioFire Respiratory 2.1 Panel). EUAs remain valid and prioritized due to the need for expanded testing capabilities. Additional full authorizations will follow as submissions are reviewed.
VERBATIM QUESTION: When will COVID-19 tests begin receiving full clearance?
VERBATIM ANSWER: The FDA has granted full marketing authorization for the first COVID 19 molecular test back in March. That was the BioFire Respiratory 2.1 Panel which included the SARS-CoV-2 virus on that panel. It was granted marketing authorization using the de novo pre-market path-- review pathway. So the grant and all subsequent molecular, essentially all subsequent molecular submissions, can then be 510k. Or, serology and antigen tests we haven't yet authorized a full authorization for those, so those first authorizations will be a grant through the de novo review pathway. And further, that this authorization of the BioFire does not impact the EUAs for any other tests. We're not pulling those EUAs from the market. We have no intention of doing that. We will continue to authorize tests through the EUA pathway and tests authorized under EUAs can be used. More full authorizations will occur as developers submit them to the FDA and our team is able to grant or clear those submissions. However, since test EUAs are still being accepted, reviewed, and authorized, they will continue to receive higher priority than full authorizations, though. And this should be for obvious reasons. That we're still looking to expand testing capability and converting an EUA to a full authorization as usual and not expanding testing and pulls our reviewers away from EUA authorizations. So we are prioritizing -- still prioritizing EUA authorizations. However, some have already come in and we anticipate authorizing more.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Full test authorization, EUA prioritization, De novo pathway
REVIEW FLAG: False

QA Block 2-3
CLARIFIED QUESTION: What is the process for obtaining full marketing authorization for a COVID-19 molecular test after receiving EUA approval?
CLARIFIED ANSWER: FDA grants full marketing authorization for molecular tests via the de novo pre-market review pathway, followed by subsequent 510(k) submissions for similar molecular tests. Serology and antigen tests will also initially pursue the de novo route once authorized.
VERBATIM QUESTION: What is the process for obtaining full marketing authorization for a COVID-19 molecular test after receiving EUA approval?
VERBATIM ANSWER: The FDA has granted full marketing authorization for the first COVID 19 molecular test back in March. That was the BioFire Respiratory 2.1 Panel which included the SARS-CoV-2 virus on that panel. It was granted marketing authorization using the de novo pre-market path-- review pathway. So the grant and all subsequent molecular, essentially all subsequent molecular submissions, can then be 510k. Or, serology and antigen tests we haven't yet authorized a full authorization for those, so those first authorizations will be a grant through the de novo review pathway. And further, that this authorization of the BioFire does not impact the EUAs for any other tests. We're not pulling those EUAs from the market. We have no intention of doing that. We will continue to authorize tests through the EUA pathway and tests authorized under EUAs can be used. More full authorizations will occur as developers submit them to the FDA and our team is able to grant or clear those submissions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Full marketing authorization, COVID-19 molecular tests, EUA vs full authorization
REVIEW FLAG: False

QA Block 2-4
CLARIFIED QUESTION: Are serology and antigen tests required to go through the de novo review pathway for their first full authorization?
CLARIFIED ANSWER: Serology and antigen tests will require authorization through the de novo review pathway for their first full authorization.
VERBATIM QUESTION: Are serology and antigen tests required to go through the de novo review pathway for their first full authorization?
VERBATIM ANSWER: Or, serology and antigen tests we haven't yet authorized a full authorization for those, so those first authorizations will be a grant through the de novo review pathway.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: serology tests, antigen tests, de novo review pathway
REVIEW FLAG: False

QA Block 2-5
CLARIFIED QUESTION: Does the FDA plan to remove previously granted EUA tests from the market once full authorizations are issued?
CLARIFIED ANSWER: The FDA does not plan to pull EUA tests from the market as full authorizations are issued. EUA-authorized tests can continue to be used.
VERBATIM QUESTION: Does the FDA plan to remove previously granted EUA tests from the market once full authorizations are issued?
VERBATIM ANSWER: The FDA has granted full marketing authorization for the first COVID 19 molecular test back in March. That was the BioFire Respiratory 2.1 Panel which included the SARS-CoV-2 virus on that panel. It was granted marketing authorization using the de novo pre-market path-- review pathway. So the grant and all subsequent molecular, essentially all subsequent molecular submissions, can then be 510k. Or, serology and antigen tests we haven't yet authorized a full authorization for those, so those first authorizations will be a grant through the de novo review pathway. And further, that this authorization of the BioFire does not impact the EUAs for any other tests. We're not pulling those EUAs from the market. We have no intention of doing that. We will continue to authorize tests through the EUA pathway and tests authorized under EUAs can be used.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA tests, full marketing authorizations, FDA testing policies
REVIEW FLAG: False

QA Block 2-6
CLARIFIED QUESTION: Why are EUA authorizations being prioritized over full authorizations for COVID-19 tests?
CLARIFIED ANSWER: The FDA is prioritizing EUA authorizations because they support the expansion of testing capacity. Converting tests from EUA to full authorization diverts resources without increasing testing availability.
VERBATIM QUESTION: Why are EUA authorizations being prioritized over full authorizations for COVID-19 tests?
VERBATIM ANSWER: However, since test EUAs are still being accepted, reviewed, and authorized, they will continue to receive higher priority than full authorizations, though. And this should be for obvious reasons. That we're still looking to expand testing capability and converting an EUA to a full authorization as usual and not expanding testing and pulls our reviewers away from EUA authorizations. So we are prioritizing -- still prioritizing EUA authorizations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA prioritization, full authorizations, COVID-19 tests
REVIEW FLAG: False

QA Block 2-7
CLARIFIED QUESTION: What steps should a test developer follow to transition from an EUA to a full authorization?
CLARIFIED ANSWER: Test developers should submit their applications for full authorization through the appropriate FDA pathways, such as the de novo review pathway for the first authorization, followed by 510(k) for subsequent molecular tests. The FDA will review and grant full authorizations as submissions are received, but EUA applications remain a priority.
VERBATIM QUESTION: What steps should a test developer follow to transition from an EUA to a full authorization?
VERBATIM ANSWER: The FDA has granted full marketing authorization for the first COVID 19 molecular test back in March. That was the BioFire Respiratory 2.1 Panel which included the SARS-CoV-2 virus on that panel. It was granted marketing authorization using the de novo pre-market review pathway. So the grant and all subsequent molecular, essentially all subsequent molecular submissions, can then be 510k. Or, serology and antigen tests we haven't yet authorized a full authorization for those, so those first authorizations will be a grant through the de novo review pathway. And further, that this authorization of the BioFire does not impact the EUAs for any other tests. We're not pulling those EUAs from the market. We have no intention of doing that. We will continue to authorize tests through the EUA pathway and tests authorized under EUAs can be used. More full authorizations will occur as developers submit them to the FDA and our team is able to grant or clear those submissions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA to full authorization transition, FDA review pathways, Test authorization priority
REVIEW FLAG: False

QA Block 2-8
CLARIFIED QUESTION: Has the FDA authorized any additional full marketing approvals for COVID-19 molecular tests beyond the BioFire Respiratory Panel 2.1?
CLARIFIED ANSWER: The FDA has not authorized any additional full marketing approvals for molecular tests since the BioFire Panel. EUAs remain prioritized for testing expansions, and more full authorizations will occur as submissions are reviewed and cleared.
VERBATIM QUESTION: Has the FDA authorized any additional full marketing approvals for COVID-19 molecular tests beyond the BioFire Respiratory Panel 2.1?
VERBATIM ANSWER: The FDA has granted full marketing authorization for the first COVID 19 molecular test back in March. That was the BioFire Respiratory 2.1 Panel which included the SARS-CoV-2 virus on that panel. It was granted marketing authorization using the de novo pre-market path-- review pathway. So the grant and all subsequent molecular, essentially all subsequent molecular submissions, can then be 510k. Or, serology and antigen tests we haven't yet authorized a full authorization for those, so those first authorizations will be a grant through the de novo review pathway. And further, that this authorization of the BioFire does not impact the EUAs for any other tests. We're not pulling those EUAs from the market. We have no intention of doing that. We will continue to authorize tests through the EUA pathway and tests authorized under EUAs can be used. More full authorizations will occur as developers submit them to the FDA and our team is able to grant or clear those submissions.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA full marketing authorization, COVID-19 molecular tests, EUA prioritization
REVIEW FLAG: False

QA Block 2-9
CLARIFIED QUESTION: What factors does the FDA consider when granting or clearing full authorization submissions for COVID-19 diagnostics?
CLARIFIED ANSWER: The FDA considers the de novo pre-market review pathway for the first authorizations, with subsequent submissions potentially using the 510(k) route. Full authorizations do not impact existing EUAs, which are prioritized to maintain testing capacity.
VERBATIM QUESTION: What factors does the FDA consider when granting or clearing full authorization submissions for COVID-19 diagnostics?
VERBATIM ANSWER: The FDA has granted full marketing authorization for the first COVID 19 molecular test back in March. That was the BioFire Respiratory 2.1 Panel which included the SARS-CoV-2 virus on that panel. It was granted marketing authorization using the de novo pre-market path-- review pathway. So the grant and all subsequent molecular, essentially all subsequent molecular submissions, can then be 510k. Or, serology and antigen tests we haven't yet authorized a full authorization for those, so those first authorizations will be a grant through the de novo review pathway. And further, that this authorization of the BioFire does not impact the EUAs for any other tests. We're not pulling those EUAs from the market. We have no intention of doing that. We will continue to authorize tests through the EUA pathway and tests authorized under EUAs can be used. More full authorizations will occur as developers submit them to the FDA and our team is able to grant or clear those submissions. However, since test EUAs are still being accepted, reviewed, and authorized, they will continue to receive higher priority than full authorizations, though. And this should be for obvious reasons. That we're still looking to expand testing capability and converting an EUA to a full authorization as usual and not expanding testing and pulls our reviewers away from EUA authorizations.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA full authorization process, COVID-19 diagnostics EUA, Testing capacity priority
REVIEW FLAG: False


#### 3. Potential Diagnostic Tools for COVID-19 Long Hauler Patients

QA Block 3-1
CLARIFIED QUESTION: Are there tests being developed to track viral loads and associate them with disease activity in COVID-19 patients, such as long haulers?
CLARIFIED ANSWER: The FDA is open to submissions for viral load tests but questions their clinical usefulness for patient management since recommendations discourage their use. Research on biomarkers and serology tests is ongoing to help diagnose long hauler patients, though limited authorization exists, like IL-6 assays.
VERBATIM QUESTION: Are there tests being developed to track viral loads and associate them with disease activity in COVID-19 patients, such as long haulers?
VERBATIM ANSWER: Of course. I don't believe that universally the long haulers still shed virus. And as far as viral load tests, which would be fully quantitative tests, if such test is something that the developer wishes to pursue, that would involve the use of calibrators linked to the international WHO standard. However, while we're open to considering such submissions, it does remain unclear to us what the clinical usefulness of such viral load assays would be. Certainly see lots of research potential for so many doing purely research and wanting to try to figure out if viral loads mean anything. We continue to monitor the literature. We also continue to monitor the CDC recommendations, other professional and lab associations and to date, they appear to uniformly discourage the use of viral loads in patient management. As far as long hauler patients go, there's likely a need to identify these patients upfront if possible or to assist in their diagnosis. We do know that there are publications that a patient who has -- suspected of long hauler disease and didn't have a diagnostic test performed when they may have been exposed and develop an infection because non symptomatic-- asymptomatic individuals can suffer from long hauler. Or some may have been symptomatic and simply didn't get-- and had a mild disease and simply didn't get a diagnostic test. So there are publications and clinicians can do their best to use serology tests to identify whether those patients have, in fact, been previously exposed to SARS. That may come in handy. And there are, we know, a number of developers who are looking at other biomarkers to try to assess risk and potentially diagnose a long hauler in addition to other clinical hallmarks of that disease. And so we do remain open to those submissions and discussions with developers for that. But we have not, other than for IL 6 which predicts potential for ventilation, we've authorized three IL 6 assays, other than that, we have not authorized any other sort of immune response assays for use in patients who suffer from more severe consequences of the virus and/or long hauler.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Viral load testing, Long haulers, Diagnostic biomarkers
REVIEW FLAG: False

QA Block 3-2
CLARIFIED QUESTION: What are the validation requirements for developing fully quantitative viral load tests?
CLARIFIED ANSWER: Developers of fully quantitative viral load tests need to use calibrators linked to the WHO standard. FDA is open to submissions but notes uncertainty regarding their clinical usefulness.
VERBATIM QUESTION: What are the validation requirements for developing fully quantitative viral load tests?
VERBATIM ANSWER: As far as viral load tests, which would be fully quantitative tests, if such test is something that the developer wishes to pursue, that would involve the use of calibrators linked to the international WHO standard. However, while we're open to considering such submissions, it does remain unclear to us what the clinical usefulness of such viral load assays would be.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation requirements, Quantitative viral load tests, FDA submission guidance
REVIEW FLAG: False

QA Block 3-3
CLARIFIED QUESTION: Is the FDA open to granting Emergency Use Authorization (EUA) for viral load tests with unclear clinical utility but potential research applications?
CLARIFIED ANSWER: The FDA is open to reviewing submissions for viral load tests, but the clinical utility of such assays remains unclear. There is significant research potential for these tests, especially for investigating the relevance of viral loads.
VERBATIM QUESTION: Is the FDA open to granting Emergency Use Authorization (EUA) for viral load tests with unclear clinical utility but potential research applications?
VERBATIM ANSWER: As far as viral load tests, which would be fully quantitative tests, if such test is something that the developer wishes to pursue, that would involve the use of calibrators linked to the international WHO standard. However, while we're open to considering such submissions, it does remain unclear to us what the clinical usefulness of such viral load assays would be. Certainly see lots of research potential for so many doing purely research and wanting to try to figure out if viral loads mean anything.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Emergency Use Authorization, viral load tests, research applications
REVIEW FLAG: False

QA Block 3-4
CLARIFIED QUESTION: Are there recommendations for identifying long hauler patients who were asymptomatic or did not receive diagnostic testing during their initial infection?
CLARIFIED ANSWER: Publications suggest using serology tests to identify prior SARS-CoV-2 exposure in patients suspected of long hauler disease who were asymptomatic or not tested during initial infection. Developers are also exploring other biomarkers to assist diagnosis.
VERBATIM QUESTION: Are there recommendations for identifying long hauler patients who were asymptomatic or did not receive diagnostic testing during their initial infection?
VERBATIM ANSWER: We do know that there are publications that a patient who has -- suspected of long hauler disease and didn't have a diagnostic test performed when they may have been exposed and develop an infection because non symptomatic-- asymptomatic individuals can suffer from long hauler. Or some may have been symptomatic and simply didn't get-- and had a mild disease and simply didn't get a diagnostic test. So there are publications and clinicians can do their best to use serology tests to identify whether those patients have, in fact, been previously exposed to SARS. That may come in handy. And there are, we know, a number of developers who are looking at other biomarkers to try to assess risk and potentially diagnose a long hauler in addition to other clinical hallmarks of that disease.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: long hauler patient identification, serology tests, biomarkers
REVIEW FLAG: False

QA Block 3-5
CLARIFIED QUESTION: Can serology tests be used to assist in diagnosing long hauler patients and what specific criteria should they meet?
CLARIFIED ANSWER: Clinicians can use serology tests to help identify if long hauler patients have been exposed to SARS-CoV-2, and developers are exploring other biomarkers to diagnose such patients. The FDA is open to submissions for these developments.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: As far as long hauler patients go, there's likely a need to identify these patients up front if possible or to assist in their diagnosis. We do know that there are publications that a patient who has -- suspected of long hauler disease and didn't have a diagnostic test performed when they may have been exposed and develop an infection because non symptomatic-- asymptomatic individuals can suffer from long hauler. Or some may have been symptomatic and simply didn't get-- and had a mild disease and simply didn't get a diagnostic test. So there are publications and clinicians can do their best to use serology tests to identify whether those patients have, in fact, been previously exposed to SARS. That may come in handy. And there are, we know, a number of developers who are looking at other biomarkers to try to assess risk and potentially diagnose a long hauler in addition to other clinical hallmarks of that disease. And so we do remain open to those submissions and discussions with developers for that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: long hauler diagnostics, serology tests, biomarker development
REVIEW FLAG: False

QA Block 3-6
CLARIFIED QUESTION: What other biomarkers is the FDA interested in for diagnosing long hauler patients beyond IL-6?
CLARIFIED ANSWER: The FDA acknowledges that developers are exploring various biomarkers to assess risk and diagnose long hauler conditions but, apart from IL-6, no other immune response assays have been authorized for this purpose.
VERBATIM QUESTION: What other biomarkers is the FDA interested in for diagnosing long hauler patients beyond IL-6?
VERBATIM ANSWER: There are, we know, a number of developers who are looking at other biomarkers to try to assess risk and potentially diagnose a long hauler in addition to other clinical hallmarks of that disease. And so we do remain open to those submissions and discussions with developers for that. But we have not, other than for IL 6 which predicts potential for ventilation, we've authorized three IL 6 assays, other than that, we have not authorized any other sort of immune response assays for use in patients who suffer from more severe consequences of the virus and/or long hauler.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Biomarkers, Long hauler diagnosis, Immune response assays
REVIEW FLAG: False

QA Block 3-7
CLARIFIED QUESTION: Are there any additional FDA-authorized immune response assays being considered for use in severe COVID-19 cases or long hauler patients?
CLARIFIED ANSWER: The FDA has authorized three IL-6 assays related to ventilation prediction but has not authorized other immune response assays for severe COVID-19 or long hauler patients.
VERBATIM QUESTION: Are there any additional FDA-authorized immune response assays being considered for use in severe COVID-19 cases or long hauler patients?
VERBATIM ANSWER: But we have not, other than for IL 6 which predicts potential for ventilation, we've authorized three IL 6 assays, other than that, we have not authorized any other sort of immune response assays for use in patients who suffer from more severe consequences of the virus and/or long hauler.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA-authorized immune response assays, Severe COVID-19 cases, Long hauler patients
REVIEW FLAG: False


#### 4. Limitations on Using Contrived Flu Samples for Validation

QA Block 4-1
CLARIFIED QUESTION: Is it possible to use contrived swab samples to prepare for an EUA submission for a rapid lateral flow test for SARS-CoV-2, flu A, and flu B antigens?
CLARIFIED ANSWER: FDA does not recommend using contrived swab samples for lateral flow tests targeting SARS-CoV-2, flu A, and flu B antigens, due to challenges with VTM and the availability of validated alternatives. Validation should use fresh samples for antigen targets where possible, ensuring results are not shared with clinicians or patients.
VERBATIM QUESTION: Is it possible to use contrived swab samples to prepare for an EUA submission for a rapid lateral flow test for SARS-CoV-2, flu A, and flu B antigens?
VERBATIM ANSWER: So we do not recommend this for a number of reasons. One is we actually don't recommend VTM for lateral flow use for SARS or really any other virus. We've just seen so-- for under an EUA, we've just seen so many challenges with VTM and VTM has been-- some sample types for some assays have needed to be pulled back because of false positives with VTM. And then the other thing is because there are cleared, fully authorized flu A, flu B, RSV, and other viruses that are available to use, we are not recommending the use of contrived samples for flu A and flu B and that would be especially for antigen tests. And so again, we mentioned at the opening that if you want to have a panel test and you're not seeing active disease for some of your targets, if you can find a way to do the validation for the targets where you do find fresh samples for antigen tests that would be awesome as long as those results aren't reported out to the clinicians and/or the patients if that's possible.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Use of contrived samples for EUA, Lateral flow test validation, Flu A and B antigen tests
REVIEW FLAG: False

QA Block 4-2
CLARIFIED QUESTION: Can swabs spiked with VTM samples be used and blinded for testing at the testing site in order to obtain a claim for flu A and B antigens?
CLARIFIED ANSWER: The FDA does not recommend using swabs spiked with VTM samples for testing, citing challenges with VTM leading to false positives and the availability of fully authorized flu A and B samples for use. Validation with fresh samples is advised, but results should not be reported to clinicians or patients.
VERBATIM QUESTION: Can swabs spiked with VTM samples be used and blinded for testing at the testing site in order to obtain a claim for flu A and B antigens?
VERBATIM ANSWER: So we do not recommend this for a number of reasons. One is we actually don't recommend VTM for lateral flow use for SARS or really any other virus. We've just seen so-- for under an EUA, we've just seen so many challenges with VTM and VTM has been-- some sample types for some assays have needed to be pulled back because of false positives with VTM. And then the other thing is because there are cleared, fully authorized flu A, flu B, RSV, and other viruses that are available to use, we are not recommending the use of contrived samples for flu A and flu B and that would be especially for antigen tests. And so again, we mentioned at the opening that if you want to have a panel test and you're not seeing active disease for some of your targets, if you can find a way to do the validation for the targets where you do find fresh samples for antigen tests that would be awesome as long as those results aren't reported out to the clinicians and/or the patients if that's possible.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: VTM sample limitations, Flu A and B validation, EUA submission
REVIEW FLAG: False

QA Block 4-3
CLARIFIED QUESTION: Why does the FDA not recommend viral transport medium (VTM) for lateral flow use for SARS-CoV-2 and other viruses?
CLARIFIED ANSWER: The FDA does not recommend viral transport medium (VTM) for lateral flow use due to challenges observed under EUAs, including false positives with some assays using VTM.
VERBATIM QUESTION: Why does the FDA not recommend viral transport medium (VTM) for lateral flow use for SARS-CoV-2 and other viruses?
VERBATIM ANSWER: We do not recommend this for a number of reasons. One is we actually don't recommend VTM for lateral flow use for SARS or really any other virus. We've just seen so-- for under an EUA, we've just seen so many challenges with VTM and VTM has been-- some sample types for some assays have needed to be pulled back because of false positives with VTM.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: VTM limitations, false positives, EUA challenges
REVIEW FLAG: False

QA Block 4-4
CLARIFIED QUESTION: What are the challenges associated with using VTM that could lead to issues during EUA authorization?
CLARIFIED ANSWER: The FDA does not recommend using VTM for lateral flow tests under an EUA due to challenges such as false positives, which have led to sample type withdrawals in some assays.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: We do not recommend this for a number of reasons. One is we actually don't recommend VTM for lateral flow use for SARS or really any other virus. We've just seen so-- for under an EUA, we've just seen so many challenges with VTM and VTM has been-- some sample types for some assays have needed to be pulled back because of false positives with VTM.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: VTM use challenges, False positives in assays, EUA submission
REVIEW FLAG: False

QA Block 4-5
CLARIFIED QUESTION: What alternatives are recommended for validation when fresh flu A or flu B samples are unavailable?
CLARIFIED ANSWER: FDA advises against using contrived samples, including swabs spiked with VTM, for flu A and flu B validation due to challenges with false positives and available authorized alternatives. If active flu samples cannot be obtained, validation should focus on targets with available fresh samples without reporting results to clinicians or patients.
VERBATIM QUESTION: What alternatives are recommended for validation when fresh flu A or flu B samples are unavailable?
VERBATIM ANSWER: We do not recommend this for a number of reasons. One is we actually don't recommend VTM for lateral flow use for SARS or really any other virus. We've just seen so-- for under an EUA, we've just seen so many challenges with VTM and VTM has been-- some sample types for some assays have needed to be pulled back because of false positives with VTM. And then the other thing is because there are cleared, fully authorized flu A, flu B, RSV, and other viruses that are available to use, we are not recommending the use of contrived samples for flu A and flu B and that would be especially for antigen tests. And so again, we mentioned at the opening that if you want to have a panel test and you're not seeing active disease for some of your targets, if you can find a way to do the validation for the targets where you do find fresh samples for antigen tests that would be awesome as long as those results aren't reported out to the clinicians and/or the patients if that's possible.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: validation alternatives, flu A and B diagnostic tests, contrived sample recommendations
REVIEW FLAG: False

QA Block 4-6
CLARIFIED QUESTION: How can developers validate a panel test for targets without active disease circulating in the community?
CLARIFIED ANSWER: FDA advises validating panel tests using fresh samples available for the targets, provided the results are not reported clinically.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: And so again, we mentioned at the opening that if you want to have a panel test and you're not seeing active disease for some of your targets, if you can find a way to do the validation for the targets where you do find fresh samples for antigen tests that would be awesome as long as those results aren't reported out to the clinicians and/or the patients if that's possible.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Validation of panel tests, Use of fresh samples for targets, Antigen testing guidance
REVIEW FLAG: False

QA Block 4-7
CLARIFIED QUESTION: Can antigen test results obtained during validation with fresh samples be used if not reported to clinicians or patients?
CLARIFIED ANSWER: The FDA permits the use of antigen test results obtained during validation with fresh samples as long as the results are not reported to clinicians or patients.
VERBATIM QUESTION: Can antigen test results obtained during validation with fresh samples be used if not reported to clinicians or patients?
VERBATIM ANSWER: And so again, we mentioned at the opening that if you want to have a panel test and you're not seeing active disease for some of your targets, if you can find a way to do the validation for the targets where you do find fresh samples for antigen tests that would be awesome as long as those results aren't reported out to the clinicians and/or the patients if that's possible.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: antigen test validation, use of fresh samples, reporting results
REVIEW FLAG: False


#### 5. FDA Guidance on Saliva-Based Flu and COVID Tests

QA Block 5-2
CLARIFIED QUESTION: If the FDA is considering EUA submissions for saliva-based multiplexed flu and COVID molecular tests, is home collection permitted?
CLARIFIED ANSWER: Home collection for saliva-based multiplexed flu and COVID molecular tests is likely possible, with several home collection kits available. Additional questions can be addressed via the FDA inbox or with a reviewer.
VERBATIM QUESTION: If the FDA is considering EUA submissions for saliva-based multiplexed flu and COVID molecular tests, is home collection permitted?
VERBATIM ANSWER: The second part is home collection and that is something that is likely possible. We do have a number of home collection kits and that specific question can be answered either via the inbox or if you have a reviewer for your test.
SPEAKER QUESTION: Kris Roth (FDA)
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: saliva-based flu and COVID molecular tests, EUA home collection, FDA review process
REVIEW FLAG: False

QA Block 5-3
CLARIFIED QUESTION: Which EUA template should be followed for saliva-based multiplexed flu and COVID molecular tests?
CLARIFIED ANSWER: FDA recommends using the molecular EUA template for saliva-based multiplex flu and COVID tests. A paired sample clinical study design is advised to compare saliva sample performance against nasopharyngeal swabs.
VERBATIM QUESTION: Which EUA template should be followed for saliva-based multiplexed flu and COVID molecular tests?
VERBATIM ANSWER: Our recommendations are to establish an EUA claim for flu. We recommend using the molecular EUA template which notes testing banked positive samples. Unfortunately, some of these samples are not available in saliva. So in lieu of that, we do recommend a paired sample clinical study design establishing performance of a saliva sample compared to nasopharyngeal swab samples.
SPEAKER QUESTION: Kris Roth (FDA)
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: EUA template, Saliva-based flu and COVID tests, Paired sample studies
REVIEW FLAG: False

QA Block 5-4
CLARIFIED QUESTION: What are the FDA's recommendations for establishing performance of saliva-based flu detection compared to nasopharyngeal swabs?
CLARIFIED ANSWER: FDA recommends a paired sample clinical study design comparing saliva samples to nasopharyngeal swabs to evaluate performance for saliva-based flu detection. This should be done prospectively, using the molecular EUA template.
VERBATIM QUESTION: IMPLICIT
VERBATIM ANSWER: Our recommendations are to establish an EUA claim for flu. We recommend using the molecular EUA template which notes testing banked positive samples. Unfortunately, some of these samples are not available in saliva. So in lieu of that, we do recommend a paired sample clinical study design establishing performance of a saliva sample compared to nasopharyngeal swab samples. To support a flu claim for saliva, this should be done prospectively.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: EUA for saliva-based flu testing, Performance comparison design, Molecular EUA template
REVIEW FLAG: False

QA Block 5-5
CLARIFIED QUESTION: Should performance studies for saliva samples use prospectively collected samples or can alternative approaches be used?
CLARIFIED ANSWER: FDA recommends a paired sample clinical study comparing saliva to nasopharyngeal swab samples. Performance studies for flu claims using saliva should be done prospectively, but challenges may arise due to low flu incidence rates.
VERBATIM QUESTION: Should performance studies for saliva samples use prospectively collected samples or can alternative approaches be used?
VERBATIM ANSWER: We do recommend a paired sample clinical study design establishing performance of a saliva sample compared to nasopharyngeal swab samples. To support a flu claim for saliva, this should be done prospectively. Furthermore, validation using fresh, prospectively collected positive samples will likely be challenging as incidents of flu infections remain low.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Saliva sample validation, Prospective studies, Flu diagnostic challenges
REVIEW FLAG: False

QA Block 5-6
CLARIFIED QUESTION: How can developers address the challenge of validating flu tests for saliva samples given the current low incidence of flu infections?
CLARIFIED ANSWER: FDA suggests a prospective paired sample clinical study comparing saliva samples to nasopharyngeal swabs, but validation is difficult due to low flu infection rates and limited data.
VERBATIM QUESTION: How can developers address the challenge of validating flu tests for saliva samples given the current low incidence of flu infections?
VERBATIM ANSWER: To support a flu claim for saliva, this should be done prospectively. Furthermore, validation using fresh, prospectively collected positive samples will likely be challenging as incidents of flu infections remain low. So this is really a data driven question and I think the suggestion here is that the data is still kind of evolving for flu in saliva.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Validation of flu tests, Saliva samples, Low flu incidence
REVIEW FLAG: False

QA Block 5-7
CLARIFIED QUESTION: Are there any specific guidelines for conducting paired sample clinical study designs to validate saliva-based flu tests?
CLARIFIED ANSWER: The FDA recommends conducting a paired sample clinical study design comparing saliva samples to nasopharyngeal swabs. This should be carried out prospectively to validate flu claims for saliva-based tests.
VERBATIM QUESTION: Are there any specific guidelines for conducting paired sample clinical study designs to validate saliva-based flu tests?
VERBATIM ANSWER: Unfortunately, some of these samples are not available in saliva. So in lieu of that, we do recommend a paired sample clinical study design establishing performance of a saliva sample compared to nasopharyngeal swab samples. To support a flu claim for saliva, this should be done prospectively.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Paired sample study design, Saliva-based flu test validation
REVIEW FLAG: False

QA Block 5-8
CLARIFIED QUESTION: What steps are recommended if banked positive saliva samples for flu testing are unavailable?
CLARIFIED ANSWER: If banked positive saliva samples are unavailable, FDA recommends conducting a paired sample clinical study comparing saliva samples to nasopharyngeal swabs, with prospective collection.
VERBATIM QUESTION: What steps are recommended if banked positive saliva samples for flu testing are unavailable?
VERBATIM ANSWER: Unfortunately, some of these samples are not available in saliva. So in lieu of that, we do recommend a paired sample clinical study design establishing performance of a saliva sample compared to nasopharyngeal swab samples. To support a flu claim for saliva, this should be done prospectively.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Flu testing, Saliva sample validation
REVIEW FLAG: False

QA Block 5-9
CLARIFIED QUESTION: What process should developers follow to propose the use of home collection kits for saliva samples in an EUA submission?
CLARIFIED ANSWER: Developers can propose the use of home collection kits for saliva samples in an EUA submission by contacting the FDA through the inbox or their test reviewer.
VERBATIM QUESTION: What process should developers follow to propose the use of home collection kits for saliva samples in an EUA submission?
VERBATIM ANSWER: The second part is home collection and that is something that is likely possible. We do have a number of home collection kits and that specific question can be answered either via the inbox or if you have a reviewer for your test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: home collection kits, saliva sample EUA process
REVIEW FLAG: False


#### 6. FDA Concerns on Saliva-Based SARS-CoV-2 Testing Validation

QA Block 6-2
CLARIFIED QUESTION: Is the FDA considering a shift to allow highly sensitive saliva-based comparator assays to validate a point-of-care test?
CLARIFIED ANSWER: The FDA does not currently consider saliva to be a better sample type than nasal swabs for validation. Saliva is considered challenging due to uncertainties in detecting other respiratory viruses, and new tests using saliva must be validated against highly sensitive molecular tests with paired NP swabs.
VERBATIM QUESTION: Is the FDA considering a shift to allow highly sensitive saliva-based comparator assays to validate a point-of-care test?
VERBATIM ANSWER: So, in our view, based on the data and the review of literature, we would not agree with the assessment of this person who sent in this question as far as saliva being a better sample type than nasal or one of the nasal swabs. Saliva, in our view, remains a very challenging sample type. Obviously it's challenging because we don't know whether flu A B or other respiratory viruses are able to be detected as accurately or accurately enough to be utilized in an assay. So we do currently still recommend that new tests utilize-- they want to use a live saliva sample validated in a clinical study compared to a paired NP swab using a highly sensitive molecular test as a comparative method.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva-based assays, validation requirements, point-of-care diagnostics
REVIEW FLAG: False

QA Block 6-3
CLARIFIED QUESTION: What are the FDA's concerns regarding the detection of Flu A, B, or other respiratory viruses using saliva samples in diagnostic assays?
CLARIFIED ANSWER: The FDA finds saliva a challenging sample type because it is uncertain if Flu A, B, or other respiratory viruses can be detected accurately enough for use in diagnostic assays.
VERBATIM QUESTION: What are the FDA's concerns regarding the detection of Flu A, B, or other respiratory viruses using saliva samples in diagnostic assays?
VERBATIM ANSWER: Saliva, in our view, remains a very challenging sample type. Obviously it's challenging because we don't know whether flu A B or other respiratory viruses are able to be detected as accurately or accurately enough to be utilized in an assay.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva sample challenges, Flu A and B detection, Respiratory virus diagnostics
REVIEW FLAG: False

QA Block 6-4
CLARIFIED QUESTION: What is the FDA's recommended process for validating new saliva-based tests in clinical studies?
CLARIFIED ANSWER: The FDA recommends validating saliva-based tests by comparing live saliva samples to paired nasopharyngeal swabs using a highly sensitive molecular test as the comparator.
VERBATIM QUESTION: What is the FDA's recommended process for validating new saliva-based tests in clinical studies?
VERBATIM ANSWER: So we do currently still recommend that new tests utilize-- they want to use a live saliva sample validated in a clinical study compared to a paired NP swab using a highly sensitive molecular test as a comparative method.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: saliva-based test validation, clinical studies, FDA recommendations
REVIEW FLAG: False

QA Block 6-5
CLARIFIED QUESTION: Why does the FDA still favor nasal swabs over saliva samples for SARS-CoV-2 testing based on current evidence?
CLARIFIED ANSWER: The FDA still favors nasal swabs over saliva samples because saliva is challenging as a sample type and may not detect respiratory viruses, such as flu A or B, accurately or reliably. New tests using saliva must be validated through clinical studies comparing it with paired nasal swabs using highly sensitive methods.
VERBATIM QUESTION: Why does the FDA still favor nasal swabs over saliva samples for SARS-CoV-2 testing based on current evidence?
VERBATIM ANSWER: So, in our view, based on the data and the review of literature, we would not agree with the assessment of this person who sent in this question as far as saliva being a better sample type than nasal or one of the nasal swabs. Saliva, in our view, remains a very challenging sample type. Obviously it's challenging because we don't know whether flu A B or other respiratory viruses are able to be detected as accurately or accurately enough to be utilized in an assay. So we do currently still recommend that new tests utilize-- they want to use a live saliva sample validated in a clinical study compared to a paired NP swab using a highly sensitive molecular test as a comparative method.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Nasal swabs vs. saliva for SARS-CoV-2 testing, Validation challenges for saliva samples, Respiratory virus detection
REVIEW FLAG: False

QA Block 6-6
CLARIFIED QUESTION: Is it mandatory to pair saliva-based sample validation with NP swabs when using a highly sensitive molecular test as a comparator?
CLARIFIED ANSWER: The FDA recommends validating saliva-based samples in a clinical study compared to paired NP swabs using a highly sensitive molecular test as a comparator.
VERBATIM QUESTION: Is it mandatory to pair saliva-based sample validation with NP swabs when using a highly sensitive molecular test as a comparator?
VERBATIM ANSWER: So we do currently still recommend that new tests utilize-- they want to use a live saliva sample validated in a clinical study compared to a paired NP swab using a highly sensitive molecular test as a comparative method.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva-based testing validation, NP swab pairing, Highly sensitive molecular tests
REVIEW FLAG: False


#### 7. Guidance on Performance Validation for COVID-19 Diagnostic Tests

QA Block 7-1
CLARIFIED QUESTION: What additional information is required to demonstrate that a clinical study includes low viral load samples?
CLARIFIED ANSWER: FDA recommends including a sufficient number of low positives, characterized by a highly sensitive RT PCR EUA test that provides CT scores, as outlined in the template.
VERBATIM QUESTION: What additional information is required to demonstrate that a clinical study includes low viral load samples?
VERBATIM ANSWER: We do recommend providing a sufficient number of low positives. And this is all covered in the template. And these low positives should be characterized by a highly sensitive RT PCR EUA test which outputs a CT score.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: low viral load samples, clinical study requirements, EUA requirements
REVIEW FLAG: False

QA Block 7-2
CLARIFIED QUESTION: Would it be acceptable, at the completion of the clinical study, to test only positive samples with an EUA authorized SARS-CoV-2 test that reports CT values?
CLARIFIED ANSWER: FDA generally accepts testing only positive samples with an EUA-authorized SARS-CoV-2 test reporting CT values, but recommends discussing specific plans with them due to potential details that may impact the approach.
VERBATIM QUESTION: Would it be acceptable, at the completion of the clinical study, to test only positive samples with an EUA authorized SARS-CoV-2 test that reports CT values?
VERBATIM ANSWER: And again, we have accepted a variety or multiple comparative methods to establish performance. So that's something that could be open. I would suggest again discussing with us first. There are details here, which may matter. So I think generally, yes. But please let us know exactly what you want to do.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: EUA test requirements, CT value reporting, Clinical study design
REVIEW FLAG: False

QA Block 7-3
CLARIFIED QUESTION: If developing a multianalyte test using the BioFire RP 2.1 as the comparative method, what information is required to demonstrate that samples with low viral load were tested for other targets such as influenza and RSV?
CLARIFIED ANSWER: The FDA recommends pre-selecting archived positive samples to represent a range of viral loads, including low positives, ensuring flu and RSV viral loads are reasonably distributed across the comparative method's range.
VERBATIM QUESTION: If developing a multianalyte test using the BioFire RP 2.1 as the comparative method, what information is required to demonstrate that samples with low viral load were tested for other targets such as influenza and RSV?
VERBATIM ANSWER: The pre-selection of archived positive samples should represent a range of viral load or CT values including low positive samples. We expect that the viral load of flu and RSV samples be reasonably distributed throughout the measuring range of the comparative method.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Multianalyte test development, BioFire RP 2.1 comparative method, Flu and RSV viral load distribution
REVIEW FLAG: False

QA Block 7-5
CLARIFIED QUESTION: Would it be acceptable to establish anterior nasal swab claims by comparing nasal swab performance on the candidate test to nasal swab results with the BioFire 2.1, provided that an LOD equivalency study for nasal and nasopharyngeal swabs is conducted for the BioFire?
CLARIFIED ANSWER: FDA generally allows anterior nasal swab comparisons for EUA, but typically grants only a nasal swab claim in such cases. Validation for other respiratory samples and an on-label EUA test as part of the comparative method are recommended.
VERBATIM QUESTION: Would it be acceptable to establish anterior nasal swab claims by comparing nasal swab performance on the candidate test to nasal swab results with the BioFire 2.1, provided that an LOD equivalency study for nasal and nasopharyngeal swabs is conducted for the BioFire?
VERBATIM ANSWER: It is generally acceptable to perform an anterior nasal swab to anterior nasal swab comparison for EUA. However, in this case, only a nasal swab claim will be granted. We recommend further validation for other respiratory sample claims. So I believe the intended use for the BioFire perhaps does not include anterior nasal swabs so I would suggest that this person, again, write up a detailed proposal explaining exactly what they would do and the justification and we can consider that going forward. But typically, we want to see an EUA test used on label as part of the comparative method.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Anterior nasal swab claims, Comparison with BioFire 2.1, Validation requirements
REVIEW FLAG: False

QA Block 7-6
CLARIFIED QUESTION: Has the FDA's Center for Devices and Radiological Health issued any specific guidance or suggestions on seeking 510k clearance for COVID assays currently under EUA?
CLARIFIED ANSWER: The FDA is working on a transition plan for devices under EUA, included in their fiscal year 2021 guidance priority list. BioFire, granted de novo clearance, is currently the only legally marketed predicate for 510k submissions until more tests are cleared. The FDA advises submitting a pre-submission to discuss validation strategies. Further discussion is needed for intended uses differing from the BioFire panel.
VERBATIM QUESTION: Has the FDA's Center for Devices and Radiological Health issued any specific guidance or suggestions on seeking 510k clearance for COVID assays currently under EUA?
VERBATIM ANSWER: We are currently working on a transition plan for devices offered under EUA. This is included in the center's guidance priority list for fiscal year '21. Since BioFire was granted at de novo, they are currently the only legally marketed predicate for 510k submission. This is, of course, until subsequent tests are cleared through the 510k pathway. FDA recommends that if you intend to pursue the 510k pathway, that you submit a pre-submission to discuss your proposed validation strategies and comparator method for review. If you are proposing an intended use which is different from the BioFire respiratory panel 2.1, then further discussion is recommended.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: 510k clearance, COVID assay transition, EUA devices
REVIEW FLAG: False

QA Block 7-7
CLARIFIED QUESTION: Is the BioFire de novo clearance the appropriate predicate for a COVID-19 assay?
CLARIFIED ANSWER: The BioFire de novo clearance is currently the only legally marketed predicate for 510k submission. FDA advises submitting a pre-submission to discuss validation strategies and comparator methods, especially if the intended use differs from the BioFire panel.
VERBATIM QUESTION: Is the BioFire de novo clearance the appropriate predicate for a COVID-19 assay?
VERBATIM ANSWER: Since BioFire was granted at de novo, they are currently the only legally marketed predicate for 510k submission. This is, of course, until subsequent tests are cleared through the 510k pathway. FDA recommends that if you intend to pursue the 510k pathway, that you submit a pre-submission to discuss your proposed validation strategies and comparator method for review. If you are proposing an intended use which is different from the BioFire respiratory panel 2.1, then further discussion is recommended.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: 510k submission process, BioFire as a predicate, Validation strategies
REVIEW FLAG: False

QA Block 7-8
CLARIFIED QUESTION: Does the readout displayed to the home user of a prescription at-home molecular SARS-CoV-2 and influenza test need to distinguish between influenza A and influenza B, or can it simply indicate whether the sample is positive or negative for influenza?
CLARIFIED ANSWER: The FDA recommends that test results differentiate between influenza A and influenza B, as this has been consistently advised for previously cleared 510k flu tests and is supported by expert opinion.
VERBATIM QUESTION: Does the readout displayed to the home user of a prescription at-home molecular SARS-CoV-2 and influenza test need to distinguish between influenza A and influenza B, or can it simply indicate whether the sample is positive or negative for influenza?
VERBATIM ANSWER: And this is a question that is quite thoroughly discussed. And we do recommend that influenza A and influenza B are differentiated as a test result. And this is based on external opinion and discussions with flu experts and has consistently been recommended for previously cleared 510k flu tests.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Test result differentiation, Influenza A and B, At-home molecular tests
REVIEW FLAG: False


#### 8. Conducting Post-Authorization Studies for Improved Assay Designs

QA Block 8-1
CLARIFIED QUESTION: Will the FDA consider allowing us to conduct the study for the improved dual target design rather than for the currently authorized single target design to support the change to the original authorization and avoid conducting the prospective study twice?
CLARIFIED ANSWER: FDA recommends directing this question to the lead reviewer handling the original authorization and any ongoing EUA submissions, as decisions depend on specific details about the tests and studies.
VERBATIM QUESTION: Will the FDA consider allowing us to conduct the study for the improved dual target design rather than for the currently authorized single target design to support the change to the original authorization and avoid conducting the prospective study twice?
VERBATIM ANSWER: Yeah. I think that's a useful question to ask our reviewers. A little bit too detailed for me to get into what test and what was the post-market study and what was the timeline for that. Obviously, if our reviewers had asked for a post-market study, it was to confirm something so that the test that's currently on market is known to be functional  so - and getting accurate results. So, but I think that's a question specifically to the lead reviewer for your first authorization. And to-- if you submitted a pre EUA or you're preparing an EUA for the second test that you include the reviewer that might be assigned to that. But I think we're going to want to know a lot more details before we give you specific advice. I don't want to say no without knowing those details that we obviously want to be as flexible as possible in our determination. OK?
SPEAKER QUESTION: Autumn Colossius
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: authorization modification, dual target design, post-market study
REVIEW FLAG: False

QA Block 8-2
CLARIFIED QUESTION: What details should be included in a submission to request a change to a post-market study requirement for an authorized test?
CLARIFIED ANSWER: The FDA recommends discussing the specifics with the lead reviewer for the first authorization and possibly involving the reviewer for a second test if applicable. They will require detailed information before advising on changes to post-market study requirements. The agency aims to remain flexible in its determination.
VERBATIM QUESTION: What details should be included in a submission to request a change to a post-market study requirement for an authorized test?
VERBATIM ANSWER: I think that's a useful question to ask our reviewers. A little bit too detailed for me to get into what test and what was the post-market study and what was the timeline for that. Obviously, if our reviewers had asked for a post-market study, it was to confirm something so that the test that's currently on market is known to be functional  so - and getting accurate results. So, but I think that's a question specifically to the lead reviewer for your first authorization. And to-- if you submitted a pre EUA or you're preparing an EUA for the second test that you include the reviewer that might be assigned to that. But I think we're going to want to know a lot more details before we give you specific advice. I don't want to say no without knowing those details that we obviously want to be as flexible as possible in our determination.
SPEAKER QUESTION: Autumn Colossius
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Post-market study requirements, Submission for test changes, Reviewer guidance
REVIEW FLAG: False

QA Block 8-3
CLARIFIED QUESTION: How can a test developer confirm if their proposed modifications align with the least burdensome approach mentioned by the FDA?
CLARIFIED ANSWER: Test developers should consult the lead reviewer for their first authorization and include the reviewer for any subsequent EUA submissions. The FDA will consider detailed information to provide flexible determinations.
VERBATIM QUESTION: How can a test developer confirm if their proposed modifications align with the least burdensome approach mentioned by the FDA?
VERBATIM ANSWER: Yeah. I think that's a useful question to ask our reviewers. A little bit too detailed for me to get into what test and what was the post-market study and what was the timeline for that. Obviously, if our reviewers had asked for a post-market study, it was to confirm something so that the test that's currently on market is known to be functional  so - and getting accurate results. So, but I think that's a question specifically to the lead reviewer for your first authorization. And to-- if you submitted a pre EUA or you're preparing an EUA for the second test that you include the reviewer that might be assigned to that. But I think we're going to want to know a lot more details before we give you specific advice. I don't want to say no without knowing those details that we obviously want to be as flexible as possible in our determination. OK?
SPEAKER QUESTION: Autumn Colossius
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: least burdensome approach, test modifications, FDA authorization process
REVIEW FLAG: False

QA Block 8-4
CLARIFIED QUESTION: What specific actions should be taken to ensure coordination with both the original test's lead reviewer and a potential reviewer for a new EUA submission?
CLARIFIED ANSWER: FDA advises contacting the lead reviewer for the original authorization and including the new reviewer for a supplemental EUA submission, ensuring sufficient details for review.
VERBATIM QUESTION: What specific actions should be taken to ensure coordination with both the original test's lead reviewer and a potential reviewer for a new EUA submission?
VERBATIM ANSWER: I think that's a useful question to ask our reviewers. A little bit too detailed for me to get into what test and what was the post-market study and what was the timeline for that. Obviously, if our reviewers had asked for a post-market study, it was to confirm something so that the test that's currently on market is known to be functional  so - and getting accurate results. So, but I think that's a question specifically to the lead reviewer for your first authorization. And to-- if you submitted a pre EUA or you're preparing an EUA for the second test that you include the reviewer that might be assigned to that. But I think we're going to want to know a lot more details before we give you specific advice. I don't want to say no without knowing those details that we obviously want to be as flexible as possible in our determination.
SPEAKER QUESTION: Autumn Colossius
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA submission process, review coordination, post-market study
REVIEW FLAG: False

QA Block 8-5
CLARIFIED QUESTION: Does the FDA have flexibility in revising post-market study requirements based on additional data or improved test designs?
CLARIFIED ANSWER: The FDA emphasizes the need for detailed information to provide specific guidance but aims to be as flexible as possible in revising post-market study requirements.
VERBATIM QUESTION: Does the FDA have flexibility in revising post-market study requirements based on additional data or improved test designs?
VERBATIM ANSWER: Yeah. I think that's a useful question to ask our reviewers. A little bit too detailed for me to get into what test and what was the post-market study and what was the timeline for that. Obviously, if our reviewers had asked for a post-market study, it was to confirm something so that the test that's currently on market is known to be functional  so - and getting accurate results. So, but I think that's a question specifically to the lead reviewer for your first authorization. And to-- if you submitted a pre EUA or you're preparing an EUA for the second test that you include the reviewer that might be assigned to that. But I think we're going to want to know a lot more details before we give you specific advice. I don't want to say no without knowing those details that we obviously want to be as flexible as possible in our determination. OK?
SPEAKER QUESTION: Autumn Colossius
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA flexibility, post-market study requirements, EUA modifications
REVIEW FLAG: False


#### 9. Availability and Options for At-Home COVID Testing

QA Block 9-1
CLARIFIED QUESTION: Are there other COVID-19 tests coming soon that can get approval?
CLARIFIED ANSWER: The FDA has authorized 13 at-home COVID-19 tests, with over 60 home collection devices available. Manufacturers are struggling to meet demand amid the Delta surge, and the government is funding production increases. The FDA prioritizes home environment test submissions and works to approve accurate tests quickly.
VERBATIM QUESTION: Are there other COVID-19 tests coming soon that can get approval?
VERBATIM ANSWER: So, yeah. Thank you for calling. And we in fact have authorized 13 at home tests. I believe at least seven varieties of them are cleared or authorized for over the counter. We're very well aware with the Delta surge that the manufacturers are struggling to keep up with the demand. And the US government is funding an increase in the production of those tests in order to try to alleviate this issue. On the other hand, we have authorized over 60, it might be over 70, home collection devices. So there's a variety of sources for those home collection through various entities as well as online sellers that are authorized to do that. So always double check. Make sure they're authorized. And many are over the counter collection devices. So no prescription is needed. The turnaround time is obviously a little bit longer than a test that you can perform at home and that should be taken into account. But I certainly know of individuals who have purchased those home collection devices where they're reasonably affordable and have a stash at home. So the other option that you have is to look at any of the national providers of testing services or local providers of testing services and they may have some options for you as well. So the national reference labs, the biggest among them are Labcorp and Quest. There are other excellent reference labs out there. And they each have home testing available as well. So you may want to check them out. It's a home collection device. Amazon has a home collection device and I apologize to the manufacturers on the call. I don't have a complete list, but the complete list of home collection devices and home tests is on the FDA website and we continue to highly prioritize tests that come in for submission for the home environment, whether it's a home test for the diagnosis of SARS or home collection for the diagnosis of SARS. So either in the home antigen or molecular tests, or for collection, it's usually a molecular test. And those remain our highest priority. And when we receive a submission that is complete and provides the evidence that we know the tests would be accurate. We have unfortunately had to deny authorization for tests that were clearly not accurate. Or perhaps in some cases where we had evidence that we could not trust the data that they submitted. And as soon as these home submissions come in and they look good, they are the very highest priorities for us to review. And overall, we now are approaching 410 test authorizations by the FDA. So there are various ways to get it but I certainly understand the current situation and it's unfortunate. And at least from the FDA perspective, by authorizing accurate tests as fast as we can, we are going to continue to do our part.
SPEAKER QUESTION: Patrick
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID-19 test authorizations, Home testing availability, FDA priorities
REVIEW FLAG: False

QA Block 9-2
CLARIFIED QUESTION: What are the currently approved at-home COVID-19 tests and where can they be accessed?
CLARIFIED ANSWER: The FDA has authorized 13 at-home tests, including at least seven over-the-counter tests, and over 60 home collection devices. Some options are available from national labs like Labcorp and Quest, online sellers, or Amazon. A full list is available on the FDA website.
VERBATIM QUESTION: What are the currently approved at-home COVID-19 tests and where can they be accessed?
VERBATIM ANSWER: So, yeah. Thank you for calling. And we in fact have authorized 13 at home tests. I believe at least seven varieties of them are cleared or authorized for over the counter. We're very well aware with the Delta surge that the manufacturers are struggling to keep up with the demand. And the US government is funding an increase in the production of those tests in order to try to alleviate this issue. On the other hand, we have authorized over 60, it might be over 70, home collection devices. So there's a variety of sources for those home collection through various entities as well as online sellers that are authorized to do that. So always double check. Make sure they're authorized. And many are over the counter collection devices. So no prescription is needed. The turnaround time is obviously a little bit longer than a test that you can perform at home and that should be taken into account. But I certainly know of individuals who have purchased those home collection devices where they're reasonably affordable and have a stash at home. So the other option that you have is to look at any of the national providers of testing services or local providers of testing services and they may have some options for you as well. So the national reference labs, the biggest among them are Labcorp and Quest. There are other excellent reference labs out there. And they each have home testing available as well. So you may want to check them out. It's a home collection device. Amazon has a home collection device and I apologize to the manufacturers on the call. I don't have a complete list, but the complete list of home collection devices and home tests is on the FDA website and we continue to highly prioritize tests that come in for submission for the home environment, whether it's a home test for the diagnosis of SARS or home collection for the diagnosis of SARS.
SPEAKER QUESTION: Patrick
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Authorized at-home COVID-19 tests, Access to home collection testing options, FDA prioritization efforts
REVIEW FLAG: False

QA Block 9-3
CLARIFIED QUESTION: What are the differences between home collection devices and at-home test kits?
CLARIFIED ANSWER: Home collection devices, unlike at-home test kits, may require longer turnaround times for results and are available over-the-counter without a prescription. They involve collecting a sample at home, while at-home test kits provide immediate results.
VERBATIM QUESTION: What are the differences between home collection devices and at-home test kits?
VERBATIM ANSWER: On the other hand, we have authorized over 60, it might be over 70, home collection devices. So there's a variety of sources for those home collection through various entities as well as online sellers that are authorized to do that. So always double check. Make sure they're authorized. And many are over the counter collection devices. So no prescription is needed. The turnaround time is obviously a little bit longer than a test that you can perform at home and that should be taken into account. But I certainly know of individuals who have purchased those home collection devices where they're reasonably affordable and have a stash at home.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home collection devices, at-home test kits, turnaround time
REVIEW FLAG: False

QA Block 9-4
CLARIFIED QUESTION: Are there specific online sellers or entities authorized to sell home collection devices?
CLARIFIED ANSWER: The FDA has authorized over 60 home collection devices, which can be accessed through various entities and authorized online sellers. It is important to verify that sellers are authorized.
VERBATIM QUESTION: Are there specific online sellers or entities authorized to sell home collection devices?
VERBATIM ANSWER: On the other hand, we have authorized over 60, it might be over 70, home collection devices. So there's a variety of sources for those home collection through various entities as well as online sellers that are authorized to do that. So always double check. Make sure they're authorized. And many are over the counter collection devices.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: online sellers, home collection devices, FDA authorizations
REVIEW FLAG: False

QA Block 9-5
CLARIFIED QUESTION: Is a prescription required to purchase home testing collection devices?
CLARIFIED ANSWER: No prescription is needed for many home collection devices, which are available over the counter through various authorized sellers.
VERBATIM QUESTION: Is a prescription required to purchase home testing collection devices?
VERBATIM ANSWER: So there's a variety of sources for those home collection through various entities as well as online sellers that are authorized to do that. So always double check. Make sure they're authorized. And many are over the counter collection devices. So no prescription is needed.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home collection devices, prescription requirements, availability
REVIEW FLAG: False

QA Block 9-6
CLARIFIED QUESTION: What is the expected turnaround time for tests sent in using home collection devices?
CLARIFIED ANSWER: The turnaround time for home collection devices is longer than for tests performed at home.
VERBATIM QUESTION: What is the expected turnaround time for tests sent in using home collection devices?
VERBATIM ANSWER: The turnaround time is obviously a little bit longer than a test that you can perform at home and that should be taken into account.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: home collection device turnaround time
REVIEW FLAG: False

QA Block 9-7
CLARIFIED QUESTION: How is the FDA prioritizing the review of submissions for new home-based COVID-19 tests?
CLARIFIED ANSWER: The FDA prioritizes submissions for home tests, including antigen and molecular, or home collection devices. Submissions that are complete and provide evidence of accuracy are reviewed as a top priority.
VERBATIM QUESTION: How is the FDA prioritizing the review of submissions for new home-based COVID-19 tests?
VERBATIM ANSWER: And we continue to highly prioritize tests that come in for submission for the home environment, whether it's a home test for the diagnosis of SARS or home collection for the diagnosis of SARS. So either in the home antigen or molecular tests, or for collection, it's usually a molecular test. And those remain our highest priority. And when we receive a submission that is complete and provides the evidence that we know the tests would be accurate. We have unfortunately had to deny authorization for tests that were clearly not accurate. Or perhaps in some cases where we had evidence that we could not trust the data that they submitted. And as soon as these home submissions come in and they look good, they are the very highest priorities for us to review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA prioritization, Home-based COVID-19 tests, Submission review process
REVIEW FLAG: False

QA Block 9-8
CLARIFIED QUESTION: What evidence is required to demonstrate the accuracy of new home-based test submissions?
CLARIFIED ANSWER: The FDA prioritizes complete submissions providing evidence of test accuracy. Tests with unreliable or untrustworthy data are denied authorization.
VERBATIM QUESTION: What evidence is required to demonstrate the accuracy of new home-based test submissions?
VERBATIM ANSWER: And those remain our highest priority. And when we receive a submission that is complete and provides the evidence that we know the tests would be accurate. We have unfortunately had to deny authorization for tests that were clearly not accurate. Or perhaps in some cases where we had evidence that we could not trust the data that they submitted. And as soon as these home submissions come in and they look good, they are the very highest priorities for us to review.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home-based COVID-19 testing, Test accuracy requirements, FDA authorization process
REVIEW FLAG: False

QA Block 9-9
CLARIFIED QUESTION: What are the reasons a new home-based test could be denied FDA authorization?
CLARIFIED ANSWER: FDA may deny authorization for home-based tests that are clearly inaccurate or if the data submitted cannot be trusted.
VERBATIM QUESTION: What are the reasons a new home-based test could be denied FDA authorization?
VERBATIM ANSWER: We have unfortunately had to deny authorization for tests that were clearly not accurate. Or perhaps in some cases where we had evidence that we could not trust the data that they submitted.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Home-based test authorization, Reasons for denial
REVIEW FLAG: False

QA Block 9-10
CLARIFIED QUESTION: Where can a complete list of FDA-authorized home collection devices and tests be found?
CLARIFIED ANSWER: The complete list of FDA-authorized home collection devices and tests is available on the FDA website.
VERBATIM QUESTION: Where can a complete list of FDA-authorized home collection devices and tests be found?
VERBATIM ANSWER: The complete list of home collection devices and home tests is on the FDA website.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA-authorized home collection devices, home tests, FDA website
REVIEW FLAG: False


#### 10. FDA's Consideration of Manufacturing Volume for Test Approvals

QA Block 10-1
CLARIFIED QUESTION: When FDA authorizes a new OTC test kit, will the manufacturing volume and supply capacity be considered as an important part?
CLARIFIED ANSWER: The FDA considers manufacturing volume and supply capacity important when authorizing OTC test kits to ensure their availability, but challenges after authorization, such as production ramp-up and distributor agreements, are outside FDA's control.
VERBATIM QUESTION: When FDA authorizes a new OTC test kit, will the manufacturing volume and supply capacity be considered as an important part?
VERBATIM ANSWER: Yeah, I can't speak to any specific test but yes. I mean, we're not going to spend a lot of time on a very low manufactured test. And having been on the other end, on the test developer side, and the ability to ramp up production is sometimes a challenge. So it does take time. You're not going to necessarily want to ramp up production until you get an EUA authorization. And also, the distributors that you might use including online and retail stores that might want to sell your test are going to want to know that your test is EUA authorized before making room on their shelves for that. So there are unfortunately real world challenges subsequent to an EUA authorization that the FDA has no control over.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: OTC test kit authorization, Manufacturing volume, Post-authorization challenges
REVIEW FLAG: False

QA Block 10-2
CLARIFIED QUESTION: Are the manufacturing volume and supply capacity factors considered due to some approved test kits not being available in the market?
CLARIFIED ANSWER: The FDA considers manufacturing volume and supply capacity, but challenges such as production ramp-up and distributor readiness post-authorization are beyond its control.
VERBATIM QUESTION: Are the manufacturing volume and supply capacity factors considered due to some approved test kits not being available in the market?
VERBATIM ANSWER: Yeah, I can't speak to any specific test but yes. I mean, we're not going to spend a lot of time on a very low manufactured test. And having been on the other end, on the test developer side, and the ability to ramp up production is sometimes a challenge. So it does take time. You're not going to necessarily want to ramp up production until you get an EUA authorization. And also, the distributors that you might use including online and retail stores that might want to sell your test are going to want to know that your test is EUA authorized before making room on their shelves for that. So there are unfortunately real world challenges subsequent to an EUA authorization that the FDA has no control over.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: manufacturing volume, supply capacity, EUA authorization challenges
REVIEW FLAG: False

QA Block 10-3
CLARIFIED QUESTION: Does the FDA consider the ability to ramp up production of a newly authorized test as a critical factor?
CLARIFIED ANSWER: The FDA considers the ability to ramp up production as important and notes challenges related to production and distribution after EUA authorization.
VERBATIM QUESTION: Does the FDA consider the ability to ramp up production of a newly authorized test as a critical factor?
VERBATIM ANSWER: Yeah, I can't speak to any specific test but yes. I mean, we're not going to spend a lot of time on a very low manufactured test. And having been on the other end, on the test developer side, and the ability to ramp up production is sometimes a challenge. So it does take time. You're not going to necessarily want to ramp up production until you get an EUA authorization. And also, the distributors that you might use including online and retail stores that might want to sell your test are going to want to know that your test is EUA authorized before making room on their shelves for that. So there are unfortunately real world challenges subsequent to an EUA authorization that the FDA has no control over.
SPEAKER QUESTION: Tianyang Liu
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: test production, EUA authorization, distribution challenges
REVIEW FLAG: False

QA Block 10-4
CLARIFIED QUESTION: What challenges might arise in distributing and selling an FDA-authorized test after EUA approval?
CLARIFIED ANSWER: Challenges after EUA approval include the need to ramp up production, gaining distributor acceptance, and ensuring online and retail store readinessall of which are outside the FDA's control.
VERBATIM QUESTION: What challenges might arise in distributing and selling an FDA-authorized test after EUA approval?
VERBATIM ANSWER: Yeah, I can't speak to any specific test but yes. I mean, we're not going to spend a lot of time on a very low manufactured test. And having been on the other end, on the test developer side, and the ability to ramp up production is sometimes a challenge. So it does take time. You're not going to necessarily want to ramp up production until you get an EUA authorization. And also, the distributors that you might use including online and retail stores that might want to sell your test are going to want to know that your test is EUA authorized before making room on their shelves for that. So there are unfortunately real world challenges subsequent to an EUA authorization that the FDA has no control over.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA challenges, Distribution hurdles, Manufacturing capacity
REVIEW FLAG: False

QA Block 10-5
CLARIFIED QUESTION: Do distributors and retailers require EUA authorization before agreeing to sell a diagnostic test?
CLARIFIED ANSWER: Distributors and retailers typically require a test to have EUA authorization before agreeing to sell it or allocating shelf space.
VERBATIM QUESTION: Do distributors and retailers require EUA authorization before agreeing to sell a diagnostic test?
VERBATIM ANSWER: And also, the distributors that you might use including online and retail stores that might want to sell your test are going to want to know that your test is EUA authorized before making room on their shelves for that.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA authorization, diagnostic test distribution, retail requirements
REVIEW FLAG: False


#### 11. Updates on Therapeutics and Emergency Use Authorization

QA Block 11-1
CLARIFIED QUESTION: Do you have any updates on therapeutics?
CLARIFIED ANSWER: The FDA's device center focuses on COVID test authorizations, not therapeutics. Questions about therapeutics should be directed to the Center for Drugs or the Center for Biologics.
VERBATIM QUESTION: Do you have any updates on therapeutics?
VERBATIM ANSWER: So we're part of the device center and this call is largely focused on COVID tests and authorization of COVID tests. The centers that would authorize therapeutics and/or vaccines would either be vaccines are authorized by the Center for Biologics. And many of the therapeutics that are authorized by the Center for Drugs, so you may be able to reach out to them to inquire as to their-- that you ask your question of them.
SPEAKER QUESTION: Sahil
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: therapeutics updates, FDA centers, Emergency Use Authorization
REVIEW FLAG: False

QA Block 11-2
CLARIFIED QUESTION: Are there any upcoming EUAs for therapeutics?
CLARIFIED ANSWER: The FDA's device center focuses on COVID tests, not therapeutics. Inquiries about EUAs for therapeutics should be directed to the Center for Drugs or the Center for Biologics.
VERBATIM QUESTION: Are there any upcoming EUAs for therapeutics?
VERBATIM ANSWER: So we're part of the device center and this call is largely focused on COVID tests and authorization of COVID tests. The centers that would authorize therapeutics and/or vaccines would either be vaccines are authorized by the Center for Biologics. And many of the therapeutics that are authorized by the Center for Drugs, so you may be able to reach out to them to inquire as to their-- that you ask your question of them.
SPEAKER QUESTION: Sahil
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUAs for therapeutics, responsible FDA centers
REVIEW FLAG: False

QA Block 11-3
CLARIFIED QUESTION: Can you approve any more therapeutics using Emergency Use Authorization?
CLARIFIED ANSWER: The FDA device center focuses on COVID test authorization. For therapeutic authorizations, inquiries should be directed to the Center for Drugs or the Center for Biologics.
VERBATIM QUESTION: Can you approve any more therapeutics using Emergency Use Authorization?
VERBATIM ANSWER: So we're part of the device center and this call is largely focused on COVID tests and authorization of COVID tests. The centers that would authorize therapeutics and/or vaccines would either be vaccines are authorized by the Center for Biologics. And many of the therapeutics that are authorized by the Center for Drugs, so you may be able to reach out to them to inquire as to their-- that you ask your question of them.
SPEAKER QUESTION: Sahil
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: COVID therapeutic EUAs, Authorization centers
REVIEW FLAG: False


#### 13. FDA Antigen Test EUA Process and Prioritization

QA Block 13-1
CLARIFIED QUESTION: How big is the team working on the EUA antigen home test?
CLARIFIED ANSWER: The team working on the EUA antigen home test is sizable and is prioritizing home and point-of-care tests, with regular weekly meetings to review and prioritize submissions.
VERBATIM QUESTION: So may I ask, how big is the team working on the EUA antigen home test?
VERBATIM ANSWER: It's a sizable team. And they and they are currently prioritizing home tests and point of care tests and I meet with them weekly, if not more.
SPEAKER QUESTION: Jack Feng
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA antigen home test team, Prioritization process, Regular meetings
REVIEW FLAG: False

QA Block 13-2
CLARIFIED QUESTION: What specific factors does the FDA prioritize when reviewing COVID-19 diagnostic submissions?
CLARIFIED ANSWER: The FDA prioritizes submissions that are complete with all necessary information provided clearly. Incomplete submissions or those requiring significant follow-up are given lower priority. Developers are advised to ensure submissions align with FDA recommendations or provide clear justifications for deviations.
VERBATIM QUESTION: What specific factors does the FDA prioritize when reviewing COVID-19 diagnostic submissions?
VERBATIM ANSWER: As I mentioned earlier, and sort of the reverse of what I said, so if a submission comes in and it's complete and our reviewers don't have to ask any questions, it gets high priority. But the reverse is also true that if a test-- if a submission is not fully complete and we have questions, it is going to not be as high priority as tests that are complete and that we can-- and all the information is there and in a manner at which we can understand how the validation was done and can move forward on those authorizations. It's incredibly rare for all of this-- for any of the submissions to be fully complete. So even on the highest priority test submissions, there is a fair bit of back and forth. And we're entirely dependent, once we've asked the question, on how fast that developer gets back to us. So the recommendation that we would have is that make sure that your submissions are complete, they're well done, that they generally follow our recommendation. That if for some reason our recommendations are not followed, that will entertain questions on our part.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: FDA review prioritization, COVID-19 diagnostics, Submission completeness
REVIEW FLAG: False

QA Block 13-4
CLARIFIED QUESTION: What is the expected timeline for feedback on submissions that have been in the queue for a long time?
CLARIFIED ANSWER: FDA is moving to a 'first in, first out' approach for antigen submissions, prioritizing feedback for those submissions that have been waiting the longest.
VERBATIM QUESTION: What is the expected timeline for feedback on submissions that have been in the queue for a long time?
VERBATIM ANSWER: For a large number of the submissions now, they are roughly at the same level of priority. And we are moving to direct at least for the antigen team to move to a first in, first out. So those that have been waiting longest for comments or a decision will hopefully hear first.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: submission feedback, EUA prioritization
REVIEW FLAG: False

QA Block 13-5
CLARIFIED QUESTION: What steps can developers take to ensure their submission is complete and aligned with FDA expectations?
CLARIFIED ANSWER: Developers should ensure their submissions are complete, follow FDA recommendations, and provide written justification if deviating from them to minimize review delays.
VERBATIM QUESTION: What steps can developers take to ensure their submission is complete and aligned with FDA expectations?
VERBATIM ANSWER: As I mentioned earlier, and sort of the reverse of what I said, so if a submission comes in and it's complete and our reviewers don't have to ask any questions, it gets high priority. But the reverse is also true that if a test-- if a submission is not fully complete and we have questions, it is going to not be as high priority as tests that are complete and that we can-- and all the information is there and in a manner at which we can understand how the validation was done and can move forward on those authorizations. It's incredibly rare for all of this-- for any of the submissions to be fully complete. So even on the highest priority test submissions, there is a fair bit of back and forth. And we're entirely dependent, once we've asked the question, on how fast that developer gets back to us. So the recommendation that we would have is that make sure that your submissions are complete, they're well done, that they generally follow our recommendation. That if for some reason our recommendations are not followed, that will entertain questions on our part. Some of those potentially could be mitigated if there's good written justification for their changes.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Submission completeness, FDA recommendations, EUA prioritization
REVIEW FLAG: False

QA Block 13-6
CLARIFIED QUESTION: What are the operational procedures of the antigen team with respect to prioritization and decision-making?
CLARIFIED ANSWER: The antigen team prioritizes home and point-of-care tests and meets weekly to review submissions and set priorities. Review efficiency depends on submission completeness, with high-priority given to complete applications. Developers are advised to submit well-prepared applications. The team handles over 100 EUA submissions monthly and increasingly follows a first-in, first-out approach for equitable handling.
VERBATIM QUESTION: What are the operational procedures of the antigen team with respect to prioritization and decision-making?
VERBATIM ANSWER: It's a sizable team. And they and they are currently prioritizing home tests and point of care tests and I meet with them weekly, if not more. Well, I meet with that specific team weekly to go over their entire submission list and prioritize their reviews. And then we also meet daily as a full team and management team and the home team can ask me any questions on any topic. So that we can move quickly. As I mentioned earlier, and sort of the reverse of what I said, so if a submission comes in and it's complete and our reviewers don't have to ask any questions, it gets high priority. But the reverse is also true that if a test-- if a submission is not fully complete and we have questions, it is going to not be as high priority as tests that are complete and that we can-- and all the information is there and in a manner at which we can understand how the validation was done and can move forward on those authorizations. It's incredibly rare for all of this-- for any of the submissions to be fully complete. So even on the highest priority test submissions, there is a fair bit of back and forth. And we're entirely dependent, once we've asked the question, on how fast that developer gets back to us. So the recommendation that we would have is that make sure that your submissions are complete, they're well done, that they generally follow our recommendation. That if for some reason our recommendations are not followed, that will entertain questions on our part. Some of those potentially could be mitigated if there's good written justification for their changes. But the workload is still high. We're still getting more than 100 EUAs a month this far into the pandemic. And as I mentioned at the top of the call, for a large number of the submissions now, they are roughly at the same level of priority. And we are moving to direct at least for the antigen team to move to a first in, first out. So those that have been waiting longest for comments or a decision will hopefully hear first.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Antigen team operations, Prioritization of submissions, EUA review process
REVIEW FLAG: False

QA Block 13-7
CLARIFIED QUESTION: How can developers provide written justifications for their changes to increase the likelihood of approval?
CLARIFIED ANSWER: Providing good written justification for any changes to FDA recommendations can potentially address questions and increase the likelihood of approval.
VERBATIM QUESTION: How can developers provide written justifications for their changes to increase the likelihood of approval?
VERBATIM ANSWER: Some of those potentially could be mitigated if there's good written justification for their changes.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: submission justifications, EUA approval process
REVIEW FLAG: False

QA Block 13-8
CLARIFIED QUESTION: What is the appropriate way to contact the FDA if there are technical issues during town hall participation?
CLARIFIED ANSWER: If there are technical issues during town hall participation, ensure you have the latest version of Zoom. Alternatively, you can email questions in advance to the town hall's provided email or use the EUA template email address for inquiries.
VERBATIM QUESTION: What is the appropriate way to contact the FDA if there are technical issues during town hall participation?
VERBATIM ANSWER: That's a good reminder at the top of the call and maybe in the email to be sure you have a current version of Zoom. And if you're not able to get through due to technical issues, you always have the email address for the upcoming town hall to ask your questions ahead of time. But we also have the EUA template email address, and you can send us an email question there and we'll endeavor to get back to you as soon as possible.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Technical issues during town hall, Contacting FDA, EUA template email
REVIEW FLAG: False

QA Block 13-9
CLARIFIED QUESTION: Where can developers find transcripts and recordings of the virtual town hall meetings?
CLARIFIED ANSWER: Transcripts and recordings of the virtual town hall meetings are available at CDRH Learn on the FDA website, under the subsection titled Coronavirus COVID-19 Test Development and Validation Virtual Town Hall Series.
VERBATIM QUESTION: Where can developers find transcripts and recordings of the virtual town hall meetings?
VERBATIM ANSWER: Today's presentation transcript will be available at CDRH Learn. Please visit CDRH Learn at www.fda.gov/Training/CDRHLearn. Note that we've updated the title of this section to make it easier to navigate. You'll now find the recordings in the subsection titled Coronavirus COVID 19 Test Development and Validation Virtual Town Hall Series.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Joseph Tartal (FDA)
TOPICS: Transcripts location, Virtual town hall recordings
REVIEW FLAG: False

QA Block 13-10
CLARIFIED QUESTION: How can developers provide feedback regarding the virtual town hall program series?
CLARIFIED ANSWER: Developers can provide feedback on the virtual town hall program series by completing a survey at www.fda.gov/CDRHWebinar.
VERBATIM QUESTION: How can developers provide feedback regarding the virtual town hall program series?
VERBATIM ANSWER: As we continue to hold these virtual town halls, we appreciate your feedback about the program series. So please complete a brief survey which you may find at www.fda.gov/CDRHWebinar.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Joseph Tartal (FDA)
TOPICS: Feedback for town hall program, Survey link
REVIEW FLAG: False

### removed qa blocks
QA Block 2-2
CLARIFIED QUESTION: Once a COVID-19 test is fully cleared, will EUA tests no longer be allowed for use?
CLARIFIED ANSWER: EUA tests will still be allowed for use even after some COVID-19 tests receive full authorization. FDA has no intention of pulling EUAs from the market and will continue authorizing tests under EUA.
VERBATIM QUESTION: Once a COVID-19 test is fully cleared, will EUA tests no longer be allowed for use?
VERBATIM ANSWER: This authorization of the BioFire does not impact the EUAs for any other tests. We're not pulling those EUAs from the market. We have no intention of doing that. We will continue to authorize tests through the EUA pathway and tests authorized under EUAs can be used.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: EUA test usage, Full test clearance, FDA authorization
REVIEW FLAG: False

QA Block 5-1
CLARIFIED QUESTION: Is the FDA considering EUA submissions for saliva-based multiplexed flu and COVID molecular tests?
CLARIFIED ANSWER: The FDA considers saliva-based flu testing to have limited supporting data and recommends using the molecular EUA template with paired sample clinical designs for validation. Home collection is likely possible, and specific questions can be addressed through the FDA inbox or assigned reviewer.
VERBATIM QUESTION: Is the FDA considering EUA submissions for saliva-based multiplexed flu and COVID molecular tests?
VERBATIM ANSWER: The data supporting flu testing using a saliva sample is limited. Also, there are no clear devices or EU tests -- EUA tests -- which are authorized for the detection of flu in a select sample. Our recommendations are to establish an EUA claim for flu. We recommend using the molecular EUA template which notes testing banked positive samples. Unfortunately, some of these samples are not available in saliva. So in lieu of that, we do recommend a paired sample clinical study design establishing performance of a saliva sample compared to nasopharyngeal swab samples. To support a flu claim for saliva, this should be done prospectively. Furthermore, validation using fresh, prospectively collected positive samples will likely be challenging as incidents of flu infections remain low. The second part is home collection and that is something that is likely possible. We do have a number of home collection kits and that specific question can be answered either via the inbox or if you have a reviewer for your test.
SPEAKER QUESTION: Kris Roth (FDA)
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Saliva-based flu and COVID testing, EUA submissions, Home collection kits
REVIEW FLAG: False

QA Block 6-1
CLARIFIED QUESTION: Does the FDA have any plans to consider saliva comparator assays for validation of new point-of-care diagnostic tests?
CLARIFIED ANSWER: The FDA does not consider saliva a better sample type than nasal swabs and finds saliva samples challenging due to uncertainties about their accuracy in detecting other respiratory viruses. FDA recommends validating saliva samples in clinical studies compared to nasal swabs using a highly sensitive molecular test.
VERBATIM QUESTION: Does the FDA have any plans to consider saliva comparator assays for validation of new point-of-care diagnostic tests?
VERBATIM ANSWER: So, in our view, based on the data and the review of literature, we would not agree with the assessment of this person who sent in this question as far as saliva being a better sample type than nasal or one of the nasal swabs. Saliva, in our view, remains a very challenging sample type. Obviously it's challenging because we don't know whether flu A B or other respiratory viruses are able to be detected as accurately or accurately enough to be utilized in an assay. So we do currently still recommend that new tests utilize-- they want to use a live saliva sample validated in a clinical study compared to a paired NP swab using a highly sensitive molecular test as a comparative method.
SPEAKER QUESTION: Tim Stenzel (FDA IVD Director)
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Saliva vs nasal swabs, Validation of saliva-based diagnostics, FDA sample validation recommendations
REVIEW FLAG: False

QA Block 7-4
CLARIFIED QUESTION: What are the performance expectations when establishing performance for an anterior nasal swab by comparing it to a paired BioFire 2.1 nasopharyngeal swab result?
CLARIFIED ANSWER: FDA expects a PTA greater than 90% and an NPA greater than 95% when comparing an anterior nasal swab performance to a paired BioFire 2.1 nasopharyngeal swab result using an FDA-cleared molecular test.
VERBATIM QUESTION: If establishing performance for an anterior nasal swab by comparing to a paired BioFire 2.1 NP swab result, what are the performance expectations?
VERBATIM ANSWER: So again, this is covered in the template. And I believe that you should definitely check with the template. But I think we're looking for a PTA of greater than 90% and an NPA of greater than 95% in comparison to an FDA cleared molecular test.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Kris Roth (FDA)
TOPICS: Performance expectations, Anterior nasal swab, BioFire 2.1 comparison
REVIEW FLAG: False

QA Block 13-3
CLARIFIED QUESTION: How should a developer address deviations from FDA recommendations in their submission?
CLARIFIED ANSWER: FDA recommends making submissions complete, well-prepared, and aligned with their guidance. If deviations occur, developers should provide justification in writing to address potential questions.
VERBATIM QUESTION: How should a developer address deviations from FDA recommendations in their submission?
VERBATIM ANSWER: The recommendation that we would have is that make sure that your submissions are complete, they're well done, that they generally follow our recommendation. That if for some reason our recommendations are not followed, that will entertain questions on our part. Some of those potentially could be mitigated if there's good written justification for their changes.
SPEAKER QUESTION: NOT APPLICABLE
SPEAKER ANSWER: Tim Stenzel (FDA IVD Director)
TOPICS: Submission quality, Deviation handling, Written justification
REVIEW FLAG: False


### extract log
#### extract log header
datetime: 2025-01-04 08:39:51 UTC-08:00 America/Los_Angeles
source file prep: primary.llm.add_transcript_section_delimiters for non-FDA speakers
ROUND 1 NAME: Explicit Questions Extraction
- prompt: FCALL_SYSTEM_PROMPT_QA_QONLY_EXPLICIT_1D
- tools: tools_qa_qonly_explicit_1
- provider: openai
- model: gpt-4o-2024-11-20

#### Section 1 of 13
##### Explicit Questions Extraction

##### Implicit Questions Extraction
QI 1-1: What are the considerations for starting validation studies within the US versus outside the US for SARS-CoV-2 tests?
QI 1-2: What should developers do if they face challenges in obtaining sufficient positive patient samples in the US for SARS-CoV-2 test validation studies?
QI 1-3: How should panel tests be validated when certain analytes, such as flu A/B, are not circulating widely in the US?
QI 1-4: Why are fresh samples recommended for validating home diagnostic assays, particularly for non-SARS viruses?
QI 1-5: In cases where fresh samples are unavailable for panel tests, what is the FDA's specific recommendation for handling the non-SARS analytes?
QI 1-6: How is the FDA currently prioritizing antigen test submissions for review and authorization?
QI 1-7: What are the current high-priority areas for serology tests from the FDA's perspective?
QI 1-8: What guidelines exist for implementing changes to EUA-authorized devices before authorization of the modification, especially concerning different testing environments (e.g., high complexity labs versus home use)?

#### Section 2 of 13
##### Explicit Questions Extraction
QE 2-1: When will COVID-19 tests begin receiving full clearance?
QE 2-2: Once a COVID-19 test is fully cleared, will EUA tests no longer be allowed for use?

##### Implicit Questions Extraction
QI 2-1: What is the process for obtaining full marketing authorization for a COVID-19 molecular test after receiving EUA approval?
QI 2-2: Are serology and antigen tests required to go through the de novo review pathway for their first full authorization?
QI 2-3: Does the FDA plan to remove previously granted EUA tests from the market once full authorizations are issued?
QI 2-4: Why are EUA authorizations being prioritized over full authorizations for COVID-19 tests?
QI 2-5: What steps should a test developer follow to transition from an EUA to a full authorization?
QI 2-6: Has the FDA authorized any additional full marketing approvals for COVID-19 molecular tests beyond the BioFire Respiratory Panel 2.1?
QI 2-7: What factors does the FDA consider when granting or clearing full authorization submissions for COVID-19 diagnostics?

#### Section 3 of 13
##### Explicit Questions Extraction
QE 3-1: Are there tests being developed to track viral loads and associate them with disease activity in COVID-19 patients, such as long haulers?

##### Implicit Questions Extraction
QI 3-1: What are the validation requirements for developing fully quantitative viral load tests?
QI 3-2: Is the FDA open to granting Emergency Use Authorization (EUA) for viral load tests with unclear clinical utility but potential research applications?
QI 3-3: Are there recommendations for identifying long hauler patients who were asymptomatic or did not receive diagnostic testing during their initial infection?
QI 3-4: Can serology tests be used to assist in diagnosing long hauler patients and what specific criteria should they meet?
QI 3-5: What other biomarkers is the FDA interested in for diagnosing long hauler patients beyond IL-6?
QI 3-6: Are there any additional FDA-authorized immune response assays being considered for use in severe COVID-19 cases or long hauler patients?

#### Section 4 of 13
##### Explicit Questions Extraction
QE 4-1: Is it possible to use contrived swab samples to prepare for an EUA submission for a rapid lateral flow test for SARS-CoV-2, flu A, and flu B antigens?
QE 4-2: Can swabs spiked with VTM samples be used and blinded for testing at the testing site in order to obtain a claim for flu A and B antigens?

##### Implicit Questions Extraction
QI 4-1: Why does the FDA not recommend viral transport medium (VTM) for lateral flow use for SARS-CoV-2 and other viruses?
QI 4-2: What are the challenges associated with using VTM that could lead to issues during EUA authorization?
QI 4-3: What alternatives are recommended for validation when fresh flu A or flu B samples are unavailable?
QI 4-4: How can developers validate a panel test for targets without active disease circulating in the community?
QI 4-5: Can antigen test results obtained during validation with fresh samples be used if not reported to clinicians or patients?

#### Section 5 of 13
##### Explicit Questions Extraction
QE 5-1: Is the FDA considering EUA submissions for saliva-based multiplexed flu and COVID molecular tests?
QE 5-2: If the FDA is considering EUA submissions for saliva-based multiplexed flu and COVID molecular tests, is home collection permitted?
QE 5-3: Which EUA template should be followed for saliva-based multiplexed flu and COVID molecular tests?

##### Implicit Questions Extraction
QI 5-1: What are the FDA's recommendations for establishing performance of saliva-based flu detection compared to nasopharyngeal swabs?
QI 5-2: Should performance studies for saliva samples use prospectively collected samples or can alternative approaches be used?
QI 5-3: How can developers address the challenge of validating flu tests for saliva samples given the current low incidence of flu infections?
QI 5-4: Are there any specific guidelines for conducting paired sample clinical study designs to validate saliva-based flu tests?
QI 5-5: What steps are recommended if banked positive saliva samples for flu testing are unavailable?
QI 5-6: What process should developers follow to propose the use of home collection kits for saliva samples in an EUA submission?

#### Section 6 of 13
##### Explicit Questions Extraction
QE 6-1: Does the FDA have any plans to consider saliva comparator assays for validation of new point-of-care diagnostic tests?
QE 6-2: Is the FDA considering a shift to allow highly sensitive saliva-based comparator assays to validate a point-of-care test?

##### Implicit Questions Extraction
QI 6-1: What are the FDA's concerns regarding the detection of Flu A, B, or other respiratory viruses using saliva samples in diagnostic assays?
QI 6-2: What is the FDA's recommended process for validating new saliva-based tests in clinical studies?
QI 6-3: Why does the FDA still favor nasal swabs over saliva samples for SARS-CoV-2 testing based on current evidence?
QI 6-4: Is it mandatory to pair saliva-based sample validation with NP swabs when using a highly sensitive molecular test as a comparator?

#### Section 7 of 13
##### Explicit Questions Extraction
QE 7-1: What additional information is required to demonstrate that a clinical study includes low viral load samples?
QE 7-2: Would it be acceptable, at the completion of the clinical study, to test only positive samples with an EUA authorized SARS-CoV-2 test that reports CT values?
QE 7-3: If developing a multianalyte test using the BioFire RP 2.1 as the comparative method, what information is required to demonstrate that samples with low viral load were tested for other targets such as influenza and RSV?
QE 7-4: What are the performance expectations when establishing performance for an anterior nasal swab by comparing it to a paired BioFire 2.1 nasopharyngeal swab result?
QE 7-5: Would it be acceptable to establish anterior nasal swab claims by comparing nasal swab performance on the candidate test to nasal swab results with the BioFire 2.1, provided that an LOD equivalency study for nasal and nasopharyngeal swabs is conducted for the BioFire?
QE 7-6: Has the FDA's Center for Devices and Radiological Health issued any specific guidance or suggestions on seeking 510k clearance for COVID assays currently under EUA?
QE 7-7: Is the BioFire de novo clearance the appropriate predicate for a COVID-19 assay?
QE 7-8: Does the readout displayed to the home user of a prescription at-home molecular SARS-CoV-2 and influenza test need to distinguish between influenza A and influenza B, or can it simply indicate whether the sample is positive or negative for influenza?

##### Implicit Questions Extraction

#### Section 8 of 13
##### Explicit Questions Extraction
QE 8-1: Will the FDA consider allowing us to conduct the study for the improved dual target design rather than for the currently authorized single target design to support the change to the original authorization and avoid conducting the prospective study twice?

##### Implicit Questions Extraction
QI 8-1: What details should be included in a submission to request a change to a post-market study requirement for an authorized test?
QI 8-2: How can a test developer confirm if their proposed modifications align with the least burdensome approach mentioned by the FDA?
QI 8-3: What specific actions should be taken to ensure coordination with both the original test's lead reviewer and a potential reviewer for a new EUA submission?
QI 8-4: Does the FDA have flexibility in revising post-market study requirements based on additional data or improved test designs?

#### Section 9 of 13
##### Explicit Questions Extraction
QE 9-1: Are there other COVID-19 tests coming soon that can get approval?

##### Implicit Questions Extraction
QI 9-1: What are the currently approved at-home COVID-19 tests and where can they be accessed?
QI 9-2: What are the differences between home collection devices and at-home test kits?
QI 9-3: Are there specific online sellers or entities authorized to sell home collection devices?
QI 9-4: Is a prescription required to purchase home testing collection devices?
QI 9-5: What is the expected turnaround time for tests sent in using home collection devices?
QI 9-6: How is the FDA prioritizing the review of submissions for new home-based COVID-19 tests?
QI 9-7: What evidence is required to demonstrate the accuracy of new home-based test submissions?
QI 9-8: What are the reasons a new home-based test could be denied FDA authorization?
QI 9-9: Where can a complete list of FDA-authorized home collection devices and tests be found?

#### Section 10 of 13
##### Explicit Questions Extraction
QE 10-1: When FDA authorizes a new OTC test kit, will the manufacturing volume and supply capacity be considered as an important part?
QE 10-2: Are the manufacturing volume and supply capacity factors considered due to some approved test kits not being available in the market?

##### Implicit Questions Extraction
QI 10-1: Does the FDA consider the ability to ramp up production of a newly authorized test as a critical factor?
QI 10-2: What challenges might arise in distributing and selling an FDA-authorized test after EUA approval?
QI 10-3: Do distributors and retailers require EUA authorization before agreeing to sell a diagnostic test?

#### Section 11 of 13
##### Explicit Questions Extraction
QE 11-1: Do you have any updates on therapeutics?
QE 11-2: Are there any upcoming EUAs for therapeutics?
QE 11-3: Can you approve any more therapeutics using Emergency Use Authorization?

##### Implicit Questions Extraction

#### Section 12 of 13
##### Explicit Questions Extraction

##### Implicit Questions Extraction

#### Section 13 of 13
##### Explicit Questions Extraction
QE 13-1: How big is the team working on the EUA antigen home test?

##### Implicit Questions Extraction
QI 13-1: What specific factors does the FDA prioritize when reviewing COVID-19 diagnostic submissions?
QI 13-2: How should a developer address deviations from FDA recommendations in their submission?
QI 13-3: What is the expected timeline for feedback on submissions that have been in the queue for a long time?
QI 13-4: What steps can developers take to ensure their submission is complete and aligned with FDA expectations?
QI 13-5: What are the operational procedures of the antigen team with respect to prioritization and decision-making?
QI 13-6: How can developers provide written justifications for their changes to increase the likelihood of approval?
QI 13-7: What is the appropriate way to contact the FDA if there are technical issues during town hall participation?
QI 13-8: Where can developers find transcripts and recordings of the virtual town hall meetings?
QI 13-9: How can developers provide feedback regarding the virtual town hall program series?
